Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel
Standard
Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. / Bonifazi, Francesca; Rubio, Marie-Thérèse; Bacigalupo, Andrea; Boelens, Jaap Jan; Finke, Jürgen; Greinix, Hildegard; Mohty, Mohamad; Nagler, Arnon; Passweg, Jakob; Rambaldi, Alessandro; Socie, Gérard; Solano, Carlos; Walker, Irwin; Barosi, Giovanni; Kröger, Nicolaus.
in: BONE MARROW TRANSPL, Jahrgang 55, Nr. 6, 06.2020, S. 1093-1102.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel
AU - Bonifazi, Francesca
AU - Rubio, Marie-Thérèse
AU - Bacigalupo, Andrea
AU - Boelens, Jaap Jan
AU - Finke, Jürgen
AU - Greinix, Hildegard
AU - Mohty, Mohamad
AU - Nagler, Arnon
AU - Passweg, Jakob
AU - Rambaldi, Alessandro
AU - Socie, Gérard
AU - Solano, Carlos
AU - Walker, Irwin
AU - Barosi, Giovanni
AU - Kröger, Nicolaus
PY - 2020/6
Y1 - 2020/6
N2 - This collaborative initiative aimed to provide recommendations on the use of polyclonal antithymocyte globulin (ATG) or anti-T lymphocyte globulin (ATLG) for the prevention of graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). A comprehensive review of articles released up to October, 2018 was performed as a source of scientific evidence. Fourteen clinically relevant key questions to the domains indication, administration, and post-transplant management were developed and recommendations were produced using the Delphi technique involving a Panel of 14 experts. ATG/ATLG was strongly recommended as part of myeloablative conditioning regimen prior to matched or mismatched unrelated bone marrow or peripheral blood allogeneic HSCT in malignant diseases to prevent severe acute and chronic GvHD. ATG/ATLG was also recommended prior to HLA-identical sibling peripheral HSCT with good but lesser bulk of evidence. In reduced intensity or nonmyeloablative conditioning regimens, ATG/ATLG was deemed appropriate to reduce the incidence of acute and chronic GvHD, but a higher risk of relapse should be taken into account. Recommendations regarding dose, application, and premedication were also provided as well as post-transplant infectious prophylaxis and vaccination. Overall, these recommendations can be used for a proper and safe application of polyclonal ATG/ATLG to prevent GvHD after allogeneic HSCT.
AB - This collaborative initiative aimed to provide recommendations on the use of polyclonal antithymocyte globulin (ATG) or anti-T lymphocyte globulin (ATLG) for the prevention of graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). A comprehensive review of articles released up to October, 2018 was performed as a source of scientific evidence. Fourteen clinically relevant key questions to the domains indication, administration, and post-transplant management were developed and recommendations were produced using the Delphi technique involving a Panel of 14 experts. ATG/ATLG was strongly recommended as part of myeloablative conditioning regimen prior to matched or mismatched unrelated bone marrow or peripheral blood allogeneic HSCT in malignant diseases to prevent severe acute and chronic GvHD. ATG/ATLG was also recommended prior to HLA-identical sibling peripheral HSCT with good but lesser bulk of evidence. In reduced intensity or nonmyeloablative conditioning regimens, ATG/ATLG was deemed appropriate to reduce the incidence of acute and chronic GvHD, but a higher risk of relapse should be taken into account. Recommendations regarding dose, application, and premedication were also provided as well as post-transplant infectious prophylaxis and vaccination. Overall, these recommendations can be used for a proper and safe application of polyclonal ATG/ATLG to prevent GvHD after allogeneic HSCT.
KW - Animals
KW - Antilymphocyte Serum/therapeutic use
KW - Consensus
KW - Graft vs Host Disease/prevention & control
KW - Hematopoietic Stem Cell Transplantation/adverse effects
KW - Neoplasm Recurrence, Local
KW - Rabbits
KW - Transplantation Conditioning
U2 - 10.1038/s41409-020-0792-x
DO - 10.1038/s41409-020-0792-x
M3 - SCORING: Review article
C2 - 31969678
VL - 55
SP - 1093
EP - 1102
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 6
ER -